Venture Report: Tubulis’ big B round to advance ADCs, Relation adds to seed financing

With investor interest in ADCs remaining high,  Tubulis GmbH announces plans to take its first two ADC candidates into the clinic with the raise of an additional €128 million ($138.8 million) in a series B2 round co-led by EQT Life Sciences and Nexttech Invest. The funding will support proof-of-concept studies for TUB-040, which targets SLC34A2 in ovarian cancer, and TUB-030, an ADC targeting 5T4 for solid tumors. 

The biotech said the first Phase I/IIa trial would start this year. In parallel, the Germany-based company plans to build out its suite of ADC technologies to include new payloads, and expand its footprint with a U.S. subsidiary. ...